HEALTH OF WOMAN. 2020.7(153): 74-83; doi 10.15574/HW.2020.153.74
Nosenko O. M.
Odessa National Medical University

The article presents modern literature data on the definition and etiopathogenesis of cervicovaginal dysbiosis caused by opportunistic microflora, as well as own data of a comparative study of the effectiveness of treatment of symptomatic cervicovaginal dysbiosis caused by a combination of bacterial vaginosis associated microorganisms and fungi of the genus Candida, using combined drugs containing ternidazole, neomycin, nystatin and prednisolone Na-metasulfobenzoate salt (Terzhinan^®) or metronidazole and miconazole.
The objective: comparing the effectiveness of treatment of symptomatic cervicovaginal dysbiosis caused by a combination of vaginally associated microorganisms and fungi of the genus Candida, using combined drugs containing ternidazole, neomycin, nystatin and salts of Na-metasulfonobenzoate prednisolone or metoconazole.
Materials and methods. The study included 107 women of reproductive age with symptomatic mixed cervicovaginal dysbiosis caused by a combination of bacterial vaginosis associated microorganisms and fungi of the genus Candida, and 30 conditionally gynecologically and somatically healthy control subjects with cervicovaginal eubiosis. Blindly examined women with cervicovaginal dysbiosis were divided into two groups: the main group – 56 patients treated with intravaginal tablets Terzhinan^®, the comparison group – 51 women who used vaginal suppositories containing metronidazole and miconazole. The dynamics of clinical data and the state of the cervicovaginal microbiota were evaluated by PCR before the start, one and three months after the end of treatment.
Results. An open comparative analysis showed that with topical therapy with Terzhinan^® vaginal tablets a month after the end of treatment, a positive clinical effect was observed in 89.29% of women and a microbiological effect in 91.07% of patients, after three months – in 85.71% and in 89.29% of patients, respectively, whereas with topical therapy with vaginal suppositories containing 750 mg of metronidazole and 200 mg of miconazole, respectively, one month after the end of treatment – in 68.73% and 72.55% of cases and after three months – in 62, 75% and 66.67% of cases.
Conclusion. Topical monotherapy with Terzhinan^® vaginal tablets in comparison with vaginal suppositories containing metronidazole and miconazole demonstrates the clinical and microbiological advantages of Terzhinan^® in the treatment of cervicovaginal dysbiosis caused by bacterial vaginosis associated microflora and yeast-like fungi of the genus Candida.
Keywords: cervicovaginal microbiota, cervicovaginal dysbiosis, opportunistic microorganisms, bacterial vaginosis associated microorganisms, yeast-like fungi of the genus Candida, Terzhinan^®, vaginal suppositories with metronidazole and miconazole, clinical efficacy, microbiological efficacy, safety, long-term results.
REFERENCES

1. Kalugina LV, Tatarchuk TF, Shakalo IN, German DG. 2016. Nonspecific vulvovaginitis of mixed othiology: local treatment is the therapy of choice. Reproductive endocrinology 1(27):94-100. https://doi.org/10.18370/2309-4117.2016.27.94-100

2. Mamchur VI, Dronov SN. 2015. Terzhinan through the eyes of a pharmacologist: an innovative approach to the treatment of vaginitis of various genesis. Medical aspects of women's health 9(95):50–57.

3. Moroz VA. 2010. Pharmacological aspects of the use of combined antimicrobial agents in the treatment of infections of the female genital area. Dermatovenereology. Cosmetology. Sexopathology 1-2:184-191.

4. Nosenko OM, Moskalenko TYa, Smirnova EV, Rutinskaya AV. 2018. Complex treatment of dysbiosis of the vaginal ecosystem caused by opportunistic bacterial and fungal flora. Medical aspects of the health of women 4(117):41-49.

5. Pirogova VI, Shurpyak SO, Feita YUR, Malachinska MY, Kuz NM. 2018. Adequate improvement of the effectiveness of topical therapy with combined drugs of decreased vaginitis, associated with cervicitis. Woman's health 6:42-49.

6. Savicheva AM, Spasibova EV. 2017. The effect of the combined preparation Terzhinan® on microorganisms isolated from the urogenital tract of women. In vitro experience. Journal of Obstetrics and Women's Diseases LXVI;5:21-26. https://doi.org/10.17816/JOWD66521-26

7. Al-Nasiry S, Ambrosino E, Schlaepfer M, Morré SA, Wieten L, Voncken JW et all. 2020. The Interplay Between Reproductive Tract Microbiota and Immunological System in Human Reproduction. Front Immunol. 11:378. Published online 2020 Mar 16. https://doi.org/10.3389/fimmu.2020.00378; PMid:32231664 PMCid:PMC7087453

8. Amsel R, Totten PA, Spiegel CA, Chen KC, Eschenbach D, Holmes KK. 1983. Nonspecific vaginitis: diagnostic criteria and microbial and epidemiologic associations. Am J Med. 74(1):14-22. https://doi.org/10.1016/0002-9343(83)91112-9

9. Anahtar MN, Gootenberg DB, Mitchell CM, Kwon DS. 2018. Cervicovaginal microbiota and reproductive health: the virtue of simplicity. Cell Host and Microbe. 23:159-68. https://doi.org/10.1016/j.chom.2018.01.013; PMid:29447695

10. Barrientos-Durán A, Fuentes-López A, de Salazar A, Plaza-Díaz J, García Julio. 2020, Feb. Reviewing the Composition of Vaginal Microbiota: Inclusion of Nutrition and Probiotic Factors in the Maintenance of Eubiosis. Nutrients. 12(2):419. Published online 2020 Feb 6. https://doi.org/10.3390/nu12020419; PMid:32041107 PMCid:PMC7071153

11. Beghini J, Linhares IM, Giraldo PC, Ledger WJ, Witkin SS. 2015. Differential expression of lactic acid isomers, extracellular matrix metalloproteinase inducer, and matrix metalloproteinase-8 in vaginal fluid from women with vaginal disorders. BJOG. 122(12):1580-1585. https://doi.org/10.1111/1471-0528.13072; PMid:25196575

12. De Seta F, Campisciano G, Zanotta N, Ricci G, Comar M. 2019. The Vaginal Community State Types Microbiome-Immune Network as Key Factor for Bacterial Vaginosis and Aerobic Vaginitis. Front Microbiol. 10:2451. Published online 2019 Oct 30. https://doi.org/10.3389/fmicb.2019.02451; PMid:31736898 PMCid:PMC6831638

13. Deng ZL, Gottschick C, Bhuju S, Masur C, Abels C, Wagner-Dobler I. 2018. Metatranscriptome Analysis of the Vaginal Microbiota Reveals Potential Mechanisms for Protection against Metronidazole in Bacterial Vaginosis. mSphere. 3:e00262-18. https://doi.org/10.1128/mSphereDirect.00262-18; PMid:29875146 PMCid:PMC5990888

14. Gajer P, Brotman RM, Bai G, Sakamoto J, Schütte UM, Zhong X et all. 2012, May. Temporal dynamics of the human vaginal microbiota. Sci Transl Med. 2;4(132):132ra52. https://doi.org/10.1126/scitranslmed.3003605; PMid:22553250 PMCid:PMC3722878

15. Hardy L, Jespers V, Van den Bulck M, Buyze J, Mwambarangwe L, Musengamana V et al. 2017. The presence of the putative Gardnerella vaginalis sialidase A gene in vaginal specimens is associated with bacterial vaginosis biofilm. PLoS ONE. 12(2):e0172522. https://doi.org/10.1371/journal.pone.0172522; PMid:28241058 PMCid:PMC5328246

16. Kalia N, Singh J, Kaur M. 2020. Microbiota in vaginal health and pathogenesis of recurrent vulvovaginal infections: a critical review. Ann Clin Microbiol Antimicrob. 19:5. Published online 2020 Jan 28. https://doi.org/10.1186/s12941-020-0347-4; PMid:31992328 PMCid:PMC6986042

17. Kroon SJ, Ravel J, Huston WM. 2018. Cervicovaginal microbiota, women's health, and reproductive outcomes. Fertil Steril. 110:327-336. https://doi.org/10.1016/j.fertnstert.2018.06.036; PMid:30098679

18. Lewis WG, Robinson LS, Gilbert NM, Perry JC, Lewis AL. 2013. Degradation, foraging, and depletion of mucus sialoglycans by the vagina-adapted Actinobacterium Gardnerella vaginalis. J Biol Chem. 288(17):12067-12079. https://doi.org/10.1074/jbc.M113.453654; PMid:23479734 PMCid:PMC3636892

19. Mason MJ, Winter AJ. 2017, Feb. How to diagnose and treat aerobic and desquamative inflammatory vaginitis. Sex Transm Infect. 93(1):8-10. https://doi.org/10.1136/sextrans-2015-052406; PMid:27272705

20. Morrill S, Gilbert NM, Lewis AL. 2020. Gardnerella vaginalis as a Cause of Bacterial Vaginosis: Appraisal of the Evidence From in vivo Models. Front Cell Infect Microbiol. 10:168. Published online 2020 Apr 24. https://doi.org/10.3389/fcimb.2020.00168; PMid:32391287 PMCid:PMC7193744

21. Nelson TM, Borgogna J-LC, Brotman RM, Ravel J, Walk ST, Yeoman CJ. 2015. Vaginal biogenic amines: biomarkers of bacterial vaginosis or precursors to vaginal dysbiosis? Front Physiol. 6:253. https://doi.org/10.3389/fphys.2015.00253

22. Parnell LA, Briggs CM, Mysorekar IU. 2017. Maternal microbiomes in preterm birth: recent progress and analytical pipelines. Semin Perinatol. 41:392-400. https://doi.org/10.1053/j.semperi.2017.07.010; PMid:28823578 PMCid:PMC6280966

23. Petrova MI, Lievens E, Malik S, Imholz N, Lebeer S. 2015. Lactobacillus species as biomarkers and agents that can promote various aspects of vaginal health. Front Physiol. 6:81. https://doi.org/10.3389/fphys.2015.00081; PMid:25859220 PMCid:PMC4373506

24. Piyathilake CJ, Ollberding NJ, Kumar R, Macaluso M, Alvarez RD, Morrow CD. 2016. Cervical Microbiota Associated with Higher Grade Cervical Intraepithelial Neoplasia in Women Infected with High-Risk Human Papillomaviruses. Cancer Prev Res. 9:357-366. https://doi.org/10.1158/1940-6207.CAPR-15-0350; PMid:26935422 PMCid:PMC4869983

25. Ravel J, Gajer P, Abdo Z, Schneider GM, Koenig SS, McCulle SL et all. 2011. Vaginal microbiome of reproductive-age women. Proc Natl Acad Sci. 108 (Supplement 1): 4680-4687. https://doi.org/10.1073/pnas.1002611107; PMid:20534435 PMCid:PMC3063603

26. Schellenberg JJ, Patterson MH, Hill JE. 2017. Gardnerella vaginalis diversity and ecology in relation to vaginal symptoms. Res Microbiol. 168(9-10):837-844. https://doi.org/10.1016/j.resmic.2017.02.011; PMid:28341009

27. Severi E, Hood DW, Thomas GH. 2007. Sialic acid utilization by bacterial pathogens. Microbiology. 153(9):2817-2822. https://doi.org/10.1099/mic.0.2007/009480-0; PMid:17768226

28. Srinivasan S, Hoffman NG, Morgan MT, Matsen FA, Fiedler TL, Hall RW et al. 2012. Bacterial communities in women with bacterial vaginosis: high resolution phylogenetic analyses reveal relationships of microbiota to clinical criteria. PLoS ONE. 7:e37818. https://doi.org/10.1371/journal.pone.0037818; PMid:22719852 PMCid:PMC3377712

29. Torcia MG. 2019. Interplay among vaginal microbiome, immune response and sexually transmitted viral infections. Int J Mol Sci. 20:E266. https://doi.org/10.3390/ijms20020266; PMid:30641869 PMCid:PMC6359169

30. Van de Wijgert JHHM, Jespers V. 2017. The global health impact of vaginal dysbiosis. Res Microbiol. 168:859-864. https://doi.org/10.1016/j.resmic.2017.02.003; PMid:28257809

31. Witkin SS, Mendes-Soares H, Linhares IM, Jayaram A, Ledger WJ, Forney LJ. 2013. Influence of Vaginal Bacteria and d- and l-Lactic Acid Isomers on Vaginal Extracellular Matrix Metalloproteinase Inducer: Implications for Protection against Upper Genital Tract Infections. mBio. 4(4):e00460-13; https://doi.org/10.1128/mBio.00460-13; PMid:23919998 PMCid:PMC3735189

32. Zilnyte M, Venclovas Č, Zvirbliene A, Pleckaityte M. 2015. The cytolytic activity of vaginolysin strictly depends on cholesterol and is potentiated by human CD59. Toxins. 7(1):110-128. https://doi.org/10.3390/toxins7010110; PMid:25590277 PMCid:PMC4303817

33. Workowski K, Berman S. 2010. Centers for disease control and prevention. Sexually transmitted diseases treatment guidelines, 2010. MMWR. Recomm. Rep. 59;12:1–110.